GlassScriptPhysician profile
Julie S Bunner
NPI 1013913011
$3,550.75
in general payments reported to CMS, 2019-2025
24 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,414 · 2020: $316 · 2021: $158 · 2022: $106 · 2023: $126 · 2024: $130 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.32 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $525.44 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $408.71 | 2019-2020 | |
| Amgen INC. | $318.29 | 2019-2025 | Evenity, Tepezza |
| Merck Sharp & Dohme LLC | $283.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $239.77 | 2019-2020 | |
| Lilly USA, LLC | $236.20 | 2019-2020 | |
| Corcept Therapeutics | $188.17 | 2019-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $168.30 | 2019-2020 | |
| Medtronic, INC. | $155.07 | 2021-2025 | Minimed 780g, Simplera Sensor |
| Valeritas, INC. | $154.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.50 | 2019-2025 | Jardiance |
| Abbvie INC. | $123.42 | 2019 | |
| Mannkind Corporation | $104.70 | 2020-2025 | |
| Averitas Pharma INC. | $94.42 | 2024-2025 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $74.57 | 2025 | |
| Insulet Corporation | $65.58 | 2019-2020 | |
| Amarin Pharma, INC. | $43.56 | 2019 | |
| Radius Health, INC. | $28.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.73 | 2025 | |
| Tandem Diabetes Care, INC. | $13.84 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 | |
| Antares Pharma, INC. | $12.26 | 2019 | |
| Medtronic Minimed, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Bunner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.